Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Wyeth is now a wholly owned subsidiary of Pfizer
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subjects with relapsing-remitting MS or secondary progressive MS with relapses.
Successful completion of study 3066A2-205-WW with no major protocol violations.
You may not be if
Pregnancy or lactation.
Clinically important abnormalities on the physical examination, vital signs, or electrocardiogram (ECG) performed at the last visit of study 3066A2-205-WW (day 252).
Any adverse events or findings observed in study 3066A2-205-WW that in the opinion of the investigators would preclude the subject's entry into the extension study.
Please refer to section 16.2 'Discontinuation and Withdrawal of Subjects' regarding withdrawal of patients who have any clinical abnormalities in hematology or laboratory test results obtained at the last visit of the double-blind active phase of study 3066A2-205-WW.
Clareo Health | Study Evaluating CCI-779 in Relapsing Multiple Sclerosis
